Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 13/20 | 0.86 |
| ▸ | CASP8 | Q14790 | 10/20 | 0.66 |
| ▸ | CASP6 | P55212 | 9/20 | 0.66 |
| ▸ | CASP1 | P29466 | 3/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.54 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113089 | 0.92 | CASP3 (0.83) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL5491249 | 0.90 | CASP3 (0.87) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL5491243 | 0.90 | CASP3 (0.87) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL5496227 | 0.87 | CASP3 (0.75) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL8548868 | 0.85 | CASP3 (0.69) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL7419603 | 0.85 | CASP3 (0.69) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL8357263 | 0.84 | CASP3 (0.82) | CASP3CASP8CASP6CASP7 | |
| SCHEMBL5489908 | 0.83 | CASP3 (0.70) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL14598407 | 0.82 | CASP3 (0.68) | CASP3CASP8CASP6CASP1CASP7 | |
| SCHEMBL6832920 | 0.82 | CASP3 (0.59) | CASP3CASP8CASP6CASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157430-B2 | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | KARANEWSKY DONALD S (US) | 2002-07-11 | — | — | US | disclosed |
| EP-1123272-A1 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242422-B1 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACUETICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000023421-A1 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CASP3 3/4885CASP8 38/4885CASP6 26/4885 |
| US-20040259804-A1 | (Substituted)Acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | CASP3 3/4885CASP8 38/4885CASP6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.